Evidence record · ER-CJC1295-GH-005
Does CJC-1295 raise growth hormone and IGF-1?
Defined long-acting CJC-1295 raises growth hormone and IGF-1 in healthy adults
CJC-1295 raised circulating growth hormone and IGF-1 in small, short human pharmacology studies of a defined long-acting formulation. That supports the hormone-response claim within the tested conditions. It does not establish muscle gain, fat loss, faster recovery, long-term safety or equivalent effects from a product sold online.
Claim boundary
What this verdict covers
The supported claim is limited to measured hormone concentrations after the defined drug used in early human studies. It does not include physique, performance, recovery or disease outcomes.
- Compound
- CJC-1295
- Population
- Healthy adults in short pharmacology studies
- Outcome
- Circulating GH and IGF-1
- Record ID
- ER-CJC1295-GH-005
Evidence synthesis
What the research can support
Two early human studies reported prolonged growth-hormone and IGF-1 responses after CJC-1295. These were pharmacodynamic studies with limited participant numbers and follow-up, designed to measure hormone exposure rather than clinical benefit.
Why the confidence is moderate
The evidence is direct for short-term hormone response but indirect for any patient-important or performance outcome. Different compounds sold as “CJC-1295”, including versions without the drug-affinity complex, are not interchangeable.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-CJC1295-GH-005 addresses one bounded question: Does CJC-1295 raise growth hormone and IGF-1?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 4 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human, the verdict is Supported and confidence is Moderate. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Human CJC-1295 pharmacology study | The study reported sustained growth-hormone and IGF-1 responses. | It did not test muscle gain, fat loss or recovery. | 10 August 2026 |
| Repeated-dose CJC-1295 human study | The study extends short-term hormone-response observations. | Small pharmacology studies do not establish long-term benefit or safety. | 10 August 2026 |
| FDA CJC-1295 safety review | FDA assessed substance identity and important human safety gaps. | The review does not verify an online product. | 10 August 2026 |
| WADA 2026 Prohibited List | Growth hormone-releasing factors are prohibited at all times. | It is a sport rule, not a clinical endorsement. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on CJC-1295 for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Two early human studies reported prolonged growth-hormone and IGF-1 responses after CJC-1295. These were pharmacodynamic studies with limited participant numbers and follow-up, designed to measure hormone exposure rather than clinical benefit. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is CJC-1295 authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Growth hormone-releasing factors, including CJC-1295, are prohibited at all times under the WADA S2 category. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
Larger controlled studies of a precisely identified product with prespecified clinical outcomes, longer follow-up and complete adverse-event surveillance. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation